ClinicalTrials.gg
Sign In

Meningioma clinical trials

The registry lists 255 studies for Meningioma across more than 10 countries. 85 are recruiting or about to start. 126 of them are mainly about Meningioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Meningioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
101
Recruiting
66
Active, not recruiting
20
Status unknown
20
Terminated
19
Not yet recruiting
16

Phase

Phase 2
80
Phase 1
51
Phase 3
12
Early Phase 1
7
Phase 4
7

Where

United States
129
France
27
China
19
Germany
10
Switzerland
9
Italy
9

Who runs them

National Cancer Institute (NCI) (12) · Central Hospital, Nancy, France (8) · Wake Forest University Health Sciences (7) · Beijing Tiantan Hospital (6) · Massachusetts General Hospital (5) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (4) · Northwestern University (4) · Weill Medical College of Cornell University (4)

What is being tested here

Drugs under test in Meningioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Lutetium Lu 177 dotatate405
Abemaciclib203
AZD 6244203
Luvometinib202
Everolimus105
ONC206102
Dexmedetomidine101
Ceritinib101
Lutetium-177101
HhAntag691101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 open · Immune checkpoint inhibitors 2 open · mTOR inhibitors 1 open · Angiogenesis inhibitors 6 · Antimetabolites 6

Coming up

3phase 3 studies under way
26studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger. 8 (12%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 6 (9%) take healthy volunteers.

Recruiting studies that take each age, of 66
AgeWomenMen
105 (8%)5 (8%)
1865 (98%)64 (97%)
3066 (100%)65 (98%)
4065 (98%)64 (97%)
5065 (98%)64 (97%)
6565 (98%)64 (97%)
7558 (88%)57 (86%)
8550 (76%)49 (74%)

Across all 255 studies, recruiting or not: 17% stop at 75 or younger and 10% at 65; 17% take children; <1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Meningioma studies take

Of 37 phase 2 interventional studies under Meningioma, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 262 mo41–108 · 37 studies——
Observational106 mo60–… · 29 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 255. Browse all 255 → or search them.